MA42016A1 - Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires - Google Patents

Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires

Info

Publication number
MA42016A1
MA42016A1 MA42016A MA42016A MA42016A1 MA 42016 A1 MA42016 A1 MA 42016A1 MA 42016 A MA42016 A MA 42016A MA 42016 A MA42016 A MA 42016A MA 42016 A1 MA42016 A1 MA 42016A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
treatment
inflammatory conditions
antagonist
ocular inflammatory
Prior art date
Application number
MA42016A
Other languages
English (en)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of MA42016A1 publication Critical patent/MA42016A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des antagonistes de l'intégrine alpha 4 et leur utilisation dans des compositions pharmaceutiques, principalement des compositions ophtalmiques administrées par voie topique. Ces compositions pharmaceutiques sont utiles pour le traitement des affections inflammatoires oculaires, par exemple la sécheresse oculaire, les uvéites non-infectieuses (par exemple, l'uvéite antérieure, postérieure, intermédiaire, la panuvéite), l'iritis, la sclérite ou la conjonctivite non-infectieux chez les
MA42016A 2015-07-08 2016-07-07 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires MA42016A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (fr) 2015-07-08 2016-07-07 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires

Publications (1)

Publication Number Publication Date
MA42016A1 true MA42016A1 (fr) 2018-03-30

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42016A MA42016A1 (fr) 2015-07-08 2016-07-07 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
MA44935A MA44935A1 (fr) 2015-07-08 2018-02-08 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44935A MA44935A1 (fr) 2015-07-08 2018-02-08 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires

Country Status (21)

Country Link
US (3) US10413535B2 (fr)
EP (1) EP3319639B1 (fr)
JP (2) JP6752276B2 (fr)
KR (2) KR20220062688A (fr)
CN (1) CN107921136A (fr)
AU (1) AU2016290197B2 (fr)
BR (1) BR112018000112A2 (fr)
CA (1) CA2989522C (fr)
CL (1) CL2018000057A1 (fr)
ES (1) ES2835274T3 (fr)
HK (1) HK1247120A1 (fr)
IL (2) IL256770B (fr)
MA (2) MA42016A1 (fr)
MX (1) MX385229B (fr)
MY (1) MY187552A (fr)
PL (1) PL3319639T3 (fr)
RU (1) RU2018103940A (fr)
TN (1) TN2017000538A1 (fr)
UA (1) UA123728C2 (fr)
WO (1) WO2017006272A1 (fr)
ZA (1) ZA201708601B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524045B2 (en) 2017-03-09 2022-12-13 Allysta Pharmaceuticals, Inc. Peptides for dry eye disease
WO2018212846A1 (fr) * 2017-05-19 2018-11-22 Ocugen, Inc. Compositions ophtalmiques et leurs procédés d'utilisation
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
HUE070112T2 (hu) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(Kinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-dion-származékok mint alpha4beta7 integrin gátlók gyulladásos betegségek kezelésére
EP3873900B1 (fr) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Dérivés de imidazo[1,2-a]pyridine en tant qu'inhibiteurs d'integrin alpha4beta7 pour le traitement de maladies inflammatoires
JP2022541851A (ja) * 2019-07-26 2022-09-27 アレグロ ファーマシューティカルズ エルエルシー 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
JP2023546915A (ja) * 2020-10-21 2023-11-08 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
PL2444079T3 (pl) * 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
AU2006311577B2 (en) * 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
EP3319639A1 (fr) 2018-05-16
CL2018000057A1 (es) 2018-06-22
IL256770A (en) 2018-03-29
ES2835274T3 (es) 2021-06-22
JP2020121985A (ja) 2020-08-13
JP6752276B2 (ja) 2020-09-09
CA2989522A1 (fr) 2017-01-12
KR20180041122A (ko) 2018-04-23
IL280827A (en) 2021-04-29
IL256770B (en) 2021-02-28
KR20220062688A (ko) 2022-05-17
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
BR112018000112A2 (pt) 2018-09-04
US20200405703A1 (en) 2020-12-31
ZA201708601B (en) 2019-05-29
KR102440162B1 (ko) 2022-09-02
AU2016290197A1 (en) 2018-01-04
MX385229B (es) 2025-03-14
CN107921136A (zh) 2018-04-17
AU2016290197B2 (en) 2021-07-22
TN2017000538A1 (en) 2019-04-12
US20200000786A1 (en) 2020-01-02
MY187552A (en) 2021-09-29
US10413535B2 (en) 2019-09-17
UA123728C2 (uk) 2021-05-26
CA2989522C (fr) 2022-10-18
JP2018521126A (ja) 2018-08-02
HK1247120A1 (zh) 2018-09-21
RU2018103940A3 (fr) 2019-09-03
WO2017006272A1 (fr) 2017-01-12
MX2017017163A (es) 2018-08-09
US20180200240A1 (en) 2018-07-19
EP3319639B1 (fr) 2020-11-18
PL3319639T3 (pl) 2021-03-08
RU2018103940A (ru) 2019-08-08

Similar Documents

Publication Publication Date Title
MA42016A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA56226B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA44948A1 (fr) Inhibiteurs de bace 1
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA202190966A1 (ru) Пролекарства антагонистов cgrp
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
MA41985B1 (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3344071A4 (fr) Compositions combinées pour réguler des niveaux de glycémie, l'hépatoprotection, et pour la prévention et le traitement d'états médicaux associés
EP3650029A4 (fr) Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP3603647A4 (fr) Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d'adénosine
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
MX378799B (es) Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.